Swiss pharmaceutical import and batch release: who decides what?

Key takeaways

• Foreign technical release and Swiss market release are distinct decisions with different accountable roles.
• Import and logistics can be outsourced only within a documented, licensed and supervised operating model.
• Direct delivery from abroad still requires written Swiss release before delivery and retained traceability.
• Official control authority batch release is a separate additional route for defined product groups.

Which release decision opens the Swiss market?

A manufacturer or foreign qualified person may certify manufacture and testing under the applicable GMP system. That evidence feeds the Swiss decision but does not replace it. Swissmedic states that the Swiss MAH is ultimately responsible when an authorised medicine is imported, and the MAH releases each relevant batch for the Swiss market under Article 13 MPLO.

The Swiss Responsible Person verifies that the batch complies with the Swiss authorisation, including composition, manufacturing process, specifications, quality, presentation and product information, and that it was manufactured according to GMP. The release record should identify the exact product, pack and batch, evidence reviewed, deviations assessed, decision, date and authorised person.

• Separate technical certification from Swiss market release
• Use the Swiss-approved product and pack specifications
• Block distribution until written release evidence exists

Sources and further reading: [1][2]

How should responsibilities be divided across the supply chain?

Map the MAH, manufacturer, importer, pre-wholesaler, warehouse, carrier, testing laboratory and any label or packaging site. For each activity, identify the required establishment licence, operational owner, Responsible Person, data exchanged and retained evidence. A commercial distribution contract alone rarely describes the quality handoffs needed for release and recall.

Swissmedic allows physical operations to be performed by appropriately licensed partners, while final market-release and recall responsibility remains with the MAH. A quality or responsibility agreement should therefore address deviations, changes, complaints, returns, temperature events, counterfeiting concerns, shortages, recalls, inspections and access to records.

Sources and further reading: [1][2][3]

What evidence should reach the Swiss Responsible Person?

The release package should be risk-based and defined before the first batch. It commonly includes foreign certification, executed batch and test summaries, approved specifications, deviation and out-of-specification status, change status, transport or temperature evidence where relevant, current presentation and product-information confirmation, and the status of complaints or safety information that could affect release. The exact package depends on the product and approved supply chain.

For the direct-delivery model described in Swissmedic’s technical interpretation, the authority also identifies sample and documentation expectations. An analysis sample sufficient for at least two complete release analyses must be retained by the manufacturer, supplier or MAH, and the MAH retains an inspection sample for each released batch. General and batch-specific manufacture and testing documents must be available. Define physical location, access, retention, replenishment and what happens after a supplier change.

• Approve a release-document index
• Define deviation and change notifications
• Locate analysis and inspection samples
• Verify access before the release clock starts

Sources and further reading: [1]

Can a product ship directly from a warehouse abroad?

Direct delivery can be possible for a medicine authorised in Switzerland, but it does not bypass Swiss responsibilities. Swissmedic’s technical interpretation says the product must be released for the Swiss market before delivery, and the written green light should be communicated to the foreign company supplying Switzerland. Responsibilities between the MAH and that company should be set out in an agreement.

The MAH must retain clear purchase and sales records so recipients can be identified completely and rapidly during a recall. It must also ensure storage and delivery under the necessary conditions and define who checks that customers are entitled to procure the products. Route qualification, customs roles and temperature-event decisions should be rehearsed before the first commercial shipment.

• Issue written green light before delivery
• Keep batch-level consignee traceability
• Define customer-eligibility checks
• Test temperature excursion and recall escalation

Sources and further reading: [1]

When is official batch release an additional requirement?

Swiss market release by the MAH should not be confused with official control authority batch release. Swissmedic’s OMCL performs official batch release for stable blood products, vaccines and other specified immunological medicines. Product lists indicate which products are subject to mandatory batch release or individual import licensing.

For qualifying products, confirm early whether an OCABR certificate can follow the applicable recognition and notification route or whether a Swiss procedure is required. Do not assume every biologic follows the same path. The product classification, current list entry, origin of official certification and import circumstances determine the evidence and sequence.

• Check the current Swissmedic product list
• Confirm certificate and notification route
• Keep official release separate from MAH market release

Sources and further reading: [3][4]

What should be tested before the first commercial shipment?

Run a paper or tabletop batch through the full chain. Verify document availability, identity matching across certificates and Swiss packs, release authority, electronic and physical quarantine status, written green light, customs and carrier instructions, sample access, temperature monitoring, consignee records and escalation contacts. A test exposes timing and interface failures without putting commercial stock at risk.

Our suggested readiness gate has three outcomes: ready, ready with controlled actions, or blocked. This is a project-control method, not an official Swissmedic category. A blocked outcome should apply when required licences, release authority, approved supply-chain details, critical records or recall traceability are missing.

• Simulate one batch from manufacture to consignee
• Test quarantine and unblocking controls
• Rehearse a temperature event and recall
• Record open actions with owners and evidence

Sources and further reading: [1][2]